g protein coupled receptor 30  (TargetMol)

Journal: International Journal of Molecular Sciences

Article Title: Bisphenol-A in Drinking Water Accelerates Mammary Cancerogenesis and Favors an Immunosuppressive Tumor Microenvironment in BALB– neu T Mice

doi: 10.3390/ijms25116259

Figure Lengend Snippet: Histological analysis and receptor status of mammary tumor tissues from BALB– neu T mice. Mammary tissues were collected from BPA-treated and untreated (CTR) BALB– neu T mice at the preinvasive or invasive stage of tumor progression (n = 3). ( A ) Hematoxylin/eosin (H/E) staining. ( B – E ) Immunostaining for ( B ) ErbB2/ neu , ( C ) αER, ( D ) GPR30, ( E ) PR, scored as described in . Tissue sections were counterstained with hematoxylin. The results are expressed as the mean ± SD values of three independent experiments performed in triplicate (* p ≤ 0.05; *** p ≤ 0.001 vs. CTR). Images were acquired with an OLYMPUS BX53 microscope (Hachioji, Tokyo, Japan) (original magnification 200×). Lower magnification images are available in .

Article Snippet: For IHC analysis, antibodies against estrogen receptor alpha (αER) (cat. no. ab241557; 1:1000), progesterone receptor (PR) (SP42; cat. no. ab101688; 1:400), and anti-G-protein coupled receptor 30 (GPR30) (cat. no. ab260033; 1:200) were purchased from Abcam (Cambridge, UK).

Techniques: Staining, Immunostaining, Microscopy

Journal: Journal for Immunotherapy of Cancer

Article Title: Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

doi: 10.1136/jitc-2020-002258

Figure Lengend Snippet: Breast cancer cells express non-canonical estrogen receptor GPR30. Specific activation of GPR30 sensitizes breast cancer cells to NK cell killing. (A) GPR30 protein expression in breast cancer cells is unaffected by tamoxifen treatment. (B) SUM149 cells were treated for 24 hours with 5 µM 4-OHT, 50 nM fulvestrant, or 50 nM G-1 and protein analyzed by apoptotic protein array. (C) SUM149 cells were treated with 50 nM fulvestrant for 24 hours followed by Annexin V/PI staining. (D) Cells were treated for 24 hours with 50 nM of specific GPR30 agonist G-1, followed by co-culture with NK cells. Cell lysis was evaluated through 111 IN-release assay at 20:1 E:T ratio. *p<0.05. (E) SUM149 cells were transfected with siCTRL or siGPR30 for 48 hours, followed by 24-hour treatment with 4-OHT or fulvestrant and co-culture with NK cells. Cell lysis was evaluated through 111 IN-release assay at 20:1 E:T ratio. *p<0.05 between treatment group and DMSO. cIAP-1, cellular inhibitor of apoptosis 1; FADD, Fas-associated death domain protein; HO-1, heme oxygenase 1; PON2, serum paraoxonase/arylesterase 2; TRAIL R1, tumor necrosis factor–related apoptosis-inducing ligand receptor 1; TRAIL R2, tumor necrosis factor–related apoptosis-inducing ligand receptor 2.

Article Snippet: G protein-coupled receptor 30 (GPR30) Agonist G-1 was obtained from Cayman Chemical (Anne Arbor, MI).

Techniques: Activation Assay, Expressing, Protein Array, Staining, Co-Culture Assay, Lysis, Release Assay, Transfection

Journal: Journal for Immunotherapy of Cancer

Article Title: Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

doi: 10.1136/jitc-2020-002258

Figure Lengend Snippet: Fulvestrant combined with N-803 decreases triple-negative breast cancer (TNBC) tumor growth in vivo. (A) Western blotting demonstrates that EMT-6 mouse TNBC cells express GPR30. (B) Flow staining of EMT-6 cells pretreated for 24 hours with 50 nM fulvestrant demonstrates increased expression of immunogenic markers MHC I and TRAIL R2, as well as PD-L1. (C) Diagram of animal experiment, n=10/group. (D) Tumor volume curve of EMT-6 tumors treated with fulvestrant, N-803, or combination (left panel). Animals treated with fulvestrant+N-803 had significantly decreased tumors on day 21 (right panel). *p<0.05.

Article Snippet: G protein-coupled receptor 30 (GPR30) Agonist G-1 was obtained from Cayman Chemical (Anne Arbor, MI).

Techniques: In Vivo, Western Blot, Staining, Expressing

Journal: Journal of Ovarian Research

Article Title: GPER-1 acts as a tumor suppressor in ovarian cancer

doi: 10.1186/1757-2215-6-51

Figure Lengend Snippet: Paraffin-embedded ovarian tumor tissue immunostained with GPER-1 antibody. GPER-1 immunostaining of ovarian cancer tissue: (A) strong positive expression in benign ovarian tumor; (B) strong positive expression in tumor of low malignant potential; (C) negative, (D) weak, (E) moderate and (F) strong positive staining of GPER-1 in ovarian cancer tissue. Original magnification: x 100.

Article Snippet: The immunostaining was performed with affinity-purified rabbit antibody against GPER-1 (SP4677P; Acris antibodies, Herford, Germany) diluted 1:500.

Techniques: Immunostaining, Expressing, Staining

Journal: Journal of Ovarian Research

Article Title: GPER-1 acts as a tumor suppressor in ovarian cancer

doi: 10.1186/1757-2215-6-51

Figure Lengend Snippet: GPER-1 protein expression and clinical outcome. A) Protein expression of GPER-1 in ovarian tumors. B) Disease-free survival of ovarian cancer patients according to GPER-1 expression. The log rank test was used to calculate the p - value.

Article Snippet: The immunostaining was performed with affinity-purified rabbit antibody against GPER-1 (SP4677P; Acris antibodies, Herford, Germany) diluted 1:500.

Techniques: Expressing

Journal: Journal of Ovarian Research

Article Title: GPER-1 acts as a tumor suppressor in ovarian cancer

doi: 10.1186/1757-2215-6-51

Figure Lengend Snippet: GPER-1 expression and G-1 effect on ovarian cancer cells. A) Representative example of GPER-1 protein expression in MCF-7 breast cancer cells and in SCOV-3 and OVCAR-3 ovarian cancer cells. ß-actin was used as a loading control. B) SCOV-3 and OVCAR-3 cells were treated with indicated concentration of G-1 and the cell number was counted using MTT viability assay. Comparison of the dose–response curves yielded IC 50 values of 3.9 μM and 0.8 μM for SCOV-3 and OVCAR-3, respectively. Each experiment was repeated at least three times. The results are expressed as means ± SD. M, marker; C, negative control (H2O).

Article Snippet: The immunostaining was performed with affinity-purified rabbit antibody against GPER-1 (SP4677P; Acris antibodies, Herford, Germany) diluted 1:500.

Techniques: Expressing, Concentration Assay, MTT Viability Assay, Marker, Negative Control

Journal: Journal of Ovarian Research

Article Title: GPER-1 acts as a tumor suppressor in ovarian cancer

doi: 10.1186/1757-2215-6-51

Figure Lengend Snippet: GPER-1 specific antagonist G-15 abolished the G-1-induced inhibitory effect in ovarian cancer cells. GPER-1-positive SCOV-3 and OVCAR-3 ovarian cancer cells and GPER-1-negative HEK-293 cells were incubated for 5 days with 1 μM G-1 with or without pre-treatment with 1 μM G-15 for 24 h and the cell number was counted using MTT viability assay. Each experiment was repeated at least three times. The results are expressed as means ± SD.

Article Snippet: The immunostaining was performed with affinity-purified rabbit antibody against GPER-1 (SP4677P; Acris antibodies, Herford, Germany) diluted 1:500.

Techniques: Incubation, MTT Viability Assay

Journal: Journal of Ovarian Research

Article Title: GPER-1 acts as a tumor suppressor in ovarian cancer

doi: 10.1186/1757-2215-6-51

Figure Lengend Snippet: GPER-1 specific agonist G-1 induced expression of cyclin B1 and Cdc2 regulatory proteins, phosphorylation of histone 3 and cleavage of pro-caspase-3. SCOV-3 (A) and OVCAR-3 (B) ovarian cancer cells were incubated with medium (control) or 1 μM G-1 for indicated times and the protein expression of cyclin B1, Cdc2 and caspase-3 as well as the phosphorylation of histone 3 were investigated by western blot analysis. ß-actin was used as a loading control. Each experiment was repeated three times.

Article Snippet: The immunostaining was performed with affinity-purified rabbit antibody against GPER-1 (SP4677P; Acris antibodies, Herford, Germany) diluted 1:500.

Techniques: Expressing, Incubation, Western Blot